Citations

Clear

3138 citation(s) found for "Smith, AM".

Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial
Badve, S. S., Zhao, F., Tung, NM, O'Sullivan, C. C., Prat, A., Winer, E. P., Wright, J. L., Recht, A., Weiss, A. C., Tjoe, J. A., Feldman, S. M., Rocque, G. B., Smith, M., Unni, N., Sardesai, S., Modi, S., Irvin, W. J., Villagrassa, P., Battelli, Chiara, Krie, A. K., Bagegni, N. A., George, M. A., Telli, M. L., Borges, V. F., D’Abreo, Nina , Shah, P. D., Miller, K. D., Partridge, A. H., Carey, L. A., DeMichele, A. M., Wolff, A. C., ECOG-ACRIN, Badve, Sunil , Tung, Nadine , Gökmen‐Polar, Yesim , O’Sullivan, Ciara C. , Prat, Aleix , Wright, J. L., Recht, A., Weiss, A. C., Rocque, Gabrielle B. , Unni, N., Sardesai, Sagar , Tang, Shou-Ching , Irvin, William , Bagegni, Nusayba , Telli, M.L., Partridge, Ann H. , Carey, L., DeMichele, Angela , Wolff, Antonio C

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS1-04-GS1-04

10.1158/1557-3265.sabcs25-gs1-04 Get It

Abstract Background: The association of TILs with pathologic complete response (pCR) and survival in HER2+ breast cancer is not well established with several prior studies showing inconsistent results. In this secondary analysis of EA1181, we evaluated the association between stromal TILs (sTILs) and pCR rates. Methods: EA1181 (NCT04266249) enrolled patients (pts) with anatomic clinical stage II/III HER2+ breast cancer who preoperatively received 4 cycles of trastuzumab and pertuzumab with 12 weeks of paclitaxel or docetaxel q3w x 4 (THP), followed by surgery. sTILs density was assessed on full-face hematoxylin and eosin (H&E)-stained tumor biopsy sections. sTILs scores were analyzed per protocol as a continuous variable (every 10% increment) and as a categorical variable (<10% vs 10-60% vs >60% as per Denkert et al, 2018), and also with an exploratory 30% cutoff commonly used in TNBC. Cox proportional hazards models were used to examine the association between sTILs and pCR, adjusting for available baseline factors. The associations between sTILs (by category) and clinicopathologic characteristics were examined using Fishers’ exact test. Results: Among 2141 pts with HER2+ BC treated on EA1181, H&E slides were available for 1328 (62%). The study population evaluated for sTILs was comparable to the overall population. pCR rates were 44.5% overall, 64% for HER2+/ER- and 33% for HER2+/ER+ disease. sTILs distribution was: 623 (47%) <10%, 698 (52%) 10-60%, and 7 (0.5%) >60%, which led us to merge the latter two groups (705 [53%] had ≥10% sTILs). In univariable and multivariable analyses, increasing sTILs (as a continuous variable) were associated with increasing pCR rates in both HER2+/ER+ and HER2+/ER- disease (p<0.001; Table). sTILs analyzed as a categorical variable (<10% vs ≥10%) were significantly associated with pCR for all patients (combined) and for those with HER2+/ER+ disease. In exploratory analysis using a cutoff of <30% vs ≥30% sTILs, an association with pCR was also seen in univariable analysis for both HER2+/ER+ disease (p<0.001) and HER2+/ER- disease (p=0.045), though in multivariable analysis with clinical factors, sTILs >30% remained a significant predictor for pCR only in HER2+/ER+ disease. Additional exploratory analysis with other molecular biomarkers, intrinsic subtypes, and immune signatures will be presented. Conclusion: sTILs were associated with pCR after THP, further supporting the important role of immune mechanisms in HER2+ breast cancer, and highlighting a potentially robust predictive tool to assess pathologic response. Baseline sTILs could potentially inform the preoperative design of future trials of therapy optimalization. Association of baseline sTILs with recurrence free survival in EA1181 will be reported in the future. Citation Format: S. S. Badve, F. Zhao, N. Tung, Y. Gokmen-Polar, C. C. O'Sullivan, A. Prat, E. P. Winer, J. L. Wright, A. Recht, A. C. Weiss, J. A. Tjoe, S. M. Feldman, G. B. Rocque, M. Smith, N. Unni, S. Sardesai, S. Tang, S. Modi, W. J. Irvin, P. Villagrassa, C. Battelli, A. K. Krie, N. Bagegni, M. A. George, M. L. Telli, V. F. Borges, N. D’Abreo, P. Shah, K. D. Miller, A. H. Partridge, L. A. Carey, A. M. DeMichele, A. C. Wolff, ECOG-ACRIN.Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS1-04.
A Celebration of International Women’s Day: Bobbi Rath Smith’s Leadership Contributions to the American Thyroid Association: Executive Director, CEO, 2001–2020
Bernet, Victor

Mayo Clinic

Thyroid® | February 13, 2026 | Volume: 36 | Issue: 3 | Pages: 227-228

10.1177/10507256261425601 | PMID 41684332 Get It

Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer
Light, Alexander, Peters, Max, Arya, Manit, Tanaka, Mariana Bertoncelli , Dudderidge, Tim , Emberton, Mark, Grey, Alistair , Hindley, Richard, Laniado, Marc, McCraken, Stuart, Moore, Caroline M., Nigam, Raj , Noureldin, Mohamed , Reddy, Deepika, Virdi, Jaspal, Ahmed, Mohamed, Albisinni, Simone, Cathcart, P. , Joniau, S., Karnes, Robert Jeffrey, Persad, Raj , Rajwa, Paweł, Sanchez-Salas, Rafael, Shariat, Shahrokh F., Smith, Joseph A., Tilki, Derya, Poel, H. G. van der, Calleris, Giorgio , Gontero, P., Marra, Giancarlo, Ahmed, Hashim U., Joniau, Steven , Emberton, Mark , Rajwa, Paweł , Moore, Caroline M. , Joniau, Steven , Rajwa, Pawel , Light, Alexander J. W., Peters, Max , Emara, Amr M. , Moore, Caroline , Orczyk, Clément , Reddy, Deepika , Albisinni, Simone , Karnes, R. Jeffrey , Shariat, Shahrokh F. , Tilki, Derya , Poel, HG van der, Marra, Giancarlo , Ahmed, Hashim U. , Shah, Taimur Tariq

Mayo Clinic

JAMA Oncology | February 12, 2026 | Volume: 12 | Issue: 4 | Pages: 364

10.1001/jamaoncol.2025.6448 | PMID 41678176 Get It

Importance Patients with recurrent prostate cancer after previous radiotherapy typically have poor survival. Those with recurrences prostate confined might be suitable for salvage focal therapy (sFT) or salvage radical prostatectomy (sRP). sFT may offer good cancer control with comparatively less toxic effects, but outcomes beyond 5 years have not been reported, and no study has compared sFT to sRP. Objective To compare cancer control and perioperative complications among patients after sFT vs sRP. Design, Setting, and Participants In this international, multicenter cohort study of matched comparison data, patients undergoing sFT were derived from the prospective UK HIFU (high-intensity focused ultrasound) Evaluation and Treatment and International Cryotherapy Evaluation registries (9 centers; 2006-2024) and the prospective UK Focal Recurrent Assessment and Salvage Treatment cohort study (6 centers; 2014-2018). Patients undergoing sRP were derived from an international retrospective registry (12 centers in 8 countries; 2000-2021). Patients with biopsy-confirmed, localized recurrent prostate cancer postradiotherapy, either external beam radiotherapy, brachytherapy, or both, were included. Data were analyzed from March to July 2025. Exposures sFT using HIFU or cryotherapy vs sRP. Main Outcomes and Measures The primary outcome was cancer-specific survival up to 10 years. Secondary outcomes were overall survival, any perioperative complications (Clavien-Dindo grades 1-5), and major perioperative complications (Clavien-Dindo grades 3-5). Comparisons were made on matched patients following 1:1 cardinality matching within individual multiply-imputed datasets. Matching variables used were radiotherapeutic treatment, years between primary and salvage treatments, European Association of Urology recurrence risk group, and presalvage age, prostate-specific antigen, prostate volume, grade group, T stage, and androgen-deprivation therapy use. Results A total of 923 patients were eligible for matching (419 undergoing sFT and 504 undergoing sRP). Of the patients undergoing sFT, 325 (77.6%) underwent HIFU and the remainder cryotherapy, with 241 (57.5%) treated with quadrant ablation. Of patients treated with sRP, 376 (74.6%) underwent open surgery and the remainder robot-assisted surgery. For sFT vs sRP, 10-year cancer-specific survival was 92% (95% CI, 86%-98%) vs 99% (95% CI, 97%-100%), with no statistically significant difference (restricted mean time lost, −0.09 years; 95% CI, −0.22 to 0.03 years; P = .15; subdistribution hazard ratio, 0.45; 95% CI, 0.05-4.00; P = .47). There was no statistically significant difference in 10-year overall survival (restricted mean survival time, −0.13 years; 95% CI, −0.86 to 0.60 years; P = .72). Undergoing sRP was associated with statistically significant higher odds of any complication (adjusted odds ratio, 24.20; 95% CI, 12.94-45.27; P < .001) and major complication (adjusted odds ratio, 9.31; 95% CI, 3.42-25.36; P < .001). Conclusions and Relevance In this cohort study, sFT and sRP were effective for treating localized radiorecurrent prostate cancer, while sFT was associated with fewer perioperative complications. sFT may provide a favorable therapeutic ratio for many patients with localized radiorecurrent prostate cancer.
Evolution of Genetics, Genetic Testing, and Genotype Predictor Scores for Hypertrophic Cardiomyopathy: Phenotype Is Still King
Bos, J. Martijn, Mj, Ackerman, Bos, J. Martijn , Bos, Johan M , Ackerman, Michael J , Ackerman, Michael J.

Mayo Clinic

Journal of the American Heart Association | February 12, 2026 | Volume: 15 | Issue: 4 | Pages: No page available

10.1161/jaha.125.047928 | PMID 41676920 Get It

The Utility of CDX2 and CK20 Immunohistochemical Reactivity to Distinguish Adenocarcinomas of the Lung From Their Benign Mimics
Li, Jiannan, Sandhu, Ariel D, Smith, Maxwell, Larsen, Brandon T. , Tazelaar, Henry D. , Bernadt, Cory T. , Ritter, Jon H. , Lin, Chieh-Yu, Wein, Alexander N. , Tazelaar, Henry D. , Lin, Chieh-Yu

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2026 | Volume: 150 | Issue: 5 | Pages: 360-364

10.5858/arpa.2025-0271-oa | PMID 41461179 Get It

Context.— Distinguishing benign from malignant processes in small lung biopsy specimens is challenging, particularly in the presence of architectural distortion and crush artifacts. Mimics include reactive type II pneumocytes in peribronchiolar metaplasia or organizing pneumonia and benign mucinous elements, including goblet cells and submucosal glands, which can mimic adenocarcinoma with mucinous features. Objective.— To understand whether caudal-type homeobox 2 (CDX2) and cytokeratin 20 (CK20) immunoreactivity is specific to malignant epithelial processes and evaluate their expression in a range of benign, premalignant, and malignant pulmonary lesions. Design.— We assessed CDX2 and CK20 immunohistochemistry in 48 cases of interstitial lung disease with reactive type II pneumocytes, 13 foci of atypical adenomatous hyperplasia, 11 bronchiolar adenomas, 4 adenocarcinomas in situ, 25 minimally invasive adenocarcinomas, 39 pulmonary adenocarcinomas with mucinous features, 6 mucoepidermoid carcinomas, and 1 squamous papilloma with goblet cell hyperplasia. Results.— No expression of CDX2 or CK20 was observed in reactive processes, goblet cells, bronchial glands, atypical adenomatous hyperplasia, or bronchiolar adenomas. In adenocarcinomas with mucinous features (n = 39), 9 (23%) were CK20-reactive and 8 (20%) were CDX2-reactive. A minority of nonmucinous and mucinous minimally invasive adenocarcinomas (n = 25) showed immunoreactivity (3 [12%] for each marker), while all in situ adenocarcinomas were negative. Conclusions.— Our findings demonstrate that CDX2 and CK20 are not expressed in benign or reactive type II pneumocytes and are specific for malignancy, particularly adenocarcinomas with mucinous features. Immunoreactivity with either marker in small biopsy specimens can support a diagnosis of malignancy, especially in morphologically equivocal or limited samples. Absence of staining does not exclude malignancy, but immunoreactivity with CDX2 and/or CK20 provides strong supportive evidence for a malignant process.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Prevalence, penetrance, and coronary heart disease risk of familial hypercholesterolemia across diverse ancestries
Dikilitas, Ozan, Hamed, M E, Smith, J, Norland, Kristján , Naderian, M, Kullo, I J, Dikilitas, Ozan , Hamed, Marwan , Naderian, Mohammadreza

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.3432 Get It

Abstract Background Contemporary prevalence and penetrance of familial hypercholesterolemia (FH) and the associated coronary heart disease (CHD) risk across diverse genetic ancestries in the United States are unclear. Purpose To estimate prevalence of individuals harboring pathogenic/likely pathogenic (P/LP) variants in LDLR, APOB, and PCSK9, distribution of low-density-lipoprotein cholesterol (LDL-C) levels, and associated CHD risk for carriers in an ancestrally diverse cohort. Methods In 242,167 All of Us (AoU) participants with available whole-genome sequencing data, we obtained LDL-C measurements, statin prescriptions, and ascertained P/LP variants in FH-related genes and presence of CHD based on electronic-health record data. P/LP variants in LDLR, APOB, and PCSK9 were identified in AoU data by filtering for high-impact (frameshift, canonical splice site, indels, and stop gain) and predicted-deleterious missense variants, then selecting those classified as P/LP in ClinVar. Untreated LDL-C levels were estimated assuming a 30% reduction if there was a record of a statin prescription in the preceding 12 months and the highest value among multiple measurements for each individual were selected. Penetrance was defined as LDL-C&gt;155 mg/dl. CHD was determined using a validated phenotyping algorithm based on diagnostic and procedural billing codes. Logistic regression models were used to obtain prevalence and penetrance estimates and odds ratios for CHD, along with associated 95% confidence intervals (95% CI). Results We identified 221 FH-related P/LP variants (LDLR=169, APOB=50, PCSK9=2) in the study cohort. Of 125,841 European (EUR), 53,367 African (AFR), 40,189 admixed American (AMR), and 22,770 other ancestry individuals, 1:218 (0.46%, 95% CI 0.42%-0.50%), 1:307 (0.33%,0.28%-0.38%), 1:350 (0.29%, 0.24%-0.34%), and 1:201 (0.50%, 0.41%-0.59%) were carriers of a P/LP variant. In 92,616 individuals with at least one LDL-C measurement, carriers of a P/LP variant had a higher distribution of LDL-C across all ancestries with similarly high penetrance (Figure 1). Harboring a P/LP variant in LDLR, APOB, and PCSK9 was associated with similarly increased odds of CHD across all the different ancestry groups (Figure 2). Conclusions Monogenic FH was prevalent, penetrant, and significantly associated with CHD similarly across diverse ancestry groups in the AoU cohort. These findings support a ‘genotype first’ approach to detection of FH to enable early intervention across diverse ancestry groups.Figure 1 Figure 2
Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits
Bains, S, Alerni, N, Oerdoeg, B, Horváth, András , Louradour, Julien , Giammarino, L, Tester, D J, Beslac, Olgica, Christoforou, Nicolas , Brunner, Michael, Casoni, Daniela , Brooks, G, Ackerman, M J, Odening, K E, Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horvath, A, Giammarino, Lucilla , Tester, David J. , Brooks, Gabriel , Odening, Katja E.

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4640 Get It

Abstract Background Short QT syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in the KCNH2-encoded Kv11.1 potassium channel, responsible for the repolarising IKr current. These variants lead to pathologically shortened cardiac repolarisation and QT intervals on 12-lead ECG, predisposing patients to life-threatening ventricular arrhythmias and sudden cardiac death. Purpose To investigate the therapeutic efficacy of our KCNH2-specific suppression-replacement gene therapy (KCNH2-SupRep) in transgenic SQT1 rabbits generated by cardiac-specific overexpression of KCNH2-N588K. Methods KCNH2-SupRep was developed by combining a custom-designed KCNH2 shRNA with its corresponding shRNA-immune KCNH2 cDNA, packaged into a single AAV9 vector and delivered directly into the aortic root via a Swan Ganz catheter (1E10 vg/kg). Therapeutic efficacy was evaluated in vivo by 12-lead ECG recordings pre- and three weeks post-therapy, ex vivo by optical voltage mapping, and at the cellular level by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs) isolated from adult transgenic SQT1 and wild-type (WT) rabbits. Results In vivo, KCNH2-SupRep normalized the heart-rate corrected QT interval (QTc) in transgenic SQT1 rabbits towards WT levels (baseline-SQT1: 153±4ms vs SupRep-SQT1: 167±5ms, p=0.0002; Fig. 1A), without adversely impacting repolarisation heterogeneity. No such QTc changes were observed in sham-treated SQT1 rabbits (sham-SQT1) (baseline-SQT1: 155±4ms vs sham-SQT1: 146±5ms, p=0.1422). Ex vivo, at a 2.5Hz stimulation frequency, KCNH2-SupRep therapeutically prolonged the APD90 in SupRep-SQT1 hearts (176±4ms) near WT levels (179±4ms), compared to untreated (UT)-SQT1 (154±4), and resolved the pathologically increased apicobasal APD90 heterogeneity observed in UT-SQT1 hearts, supporting an anti-arrhythmic effect of KCNH2-SupRep (Fig. 1B). At the cellular level, at a 1Hz stimulation frequency, KCNH2-SupRep prolonged the APD90 in VCMs isolated from SupRep-SQT1 rabbits (363±11ms) closer to WT levels (404±14ms) as compared to UT- (314±12ms) and sham-SQT1 (322±11ms; Fig. 1C). Moreover, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window (cEMW, Ca2+ transient duration – APD) and normalized IKr in nearly 50% of VCMs (Fig. 1D), in line with a 50-60% suppression of the mutant KCNH2 transcript. This partial therapeutic effect on IKr may explain the incomplete APD90 normalization in individual VCMs. Nonetheless, both in vivo and ex vivo, this partial therapeutic effect was sufficient to completely restore the electrical properties. Conclusion This proof-of-concept study is the first to demonstrate the efficacy of gene therapy in treating SQT1 in a medium-sized animal model. KCNH2-SupRep rescued the disease phenotype in vivo, ex vivo and at cellular levels in transgenic SQT1 rabbits.Therapeutic efficacy of KCNH2-SupRep
Quantitative bias analyses to address measurement error in time-to-event endpoints
Ackerman, Benjamin , Gan, Ryan W. , Zhang, Youyi, Hayden, Jennifer, Wang, Jocelyn R., Meyer, Craig S. , Lund, Jennifer L., Schneeweiss, S, Roose, James , Nadeem, Omar, NS, Raje, Giri, Smith, Hester, Laura , Brayer, Jason , Batavia, Ashita S. , Schneeweiß, Sebastian , Lund, Jennifer L , Schneeweiss, Sebastian , Stürmer, Til , Siddique, Juned , Weberpals, Janick G. , Nadeem, Omar , Ailawadhi, Sikander

Mayo Clinic

American Journal of Epidemiology | February 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/aje/kwag027 | PMID 41645621 Get It

Abstract When using real-world data to construct an external comparator arm for a single-arm trial, there may be differences in how and when patients are assessed for disease between trial and real-world settings. Such differences can generate outcome measurement error when comparing time-to-event endpoints and lead to biased findings. Recent methods have been developed to mitigate measurement error bias in real-world endpoints; however, they rely on the existence of a validation sample, ie, data on a set of patients where both the “true” trial-like and “mis-measured” real-world measures are collected. We demonstrate how novel statistical methods can be leveraged as quantitative bias analyses (QBA) to contextualize real-world evidence findings when outcome measurement error is of concern, but validation samples are infeasible to collect. Quantitative bias analyses allow researchers to set plausible ranges for the amount of error when not directly measurable. We highlight how to conduct QBA with two recent methods, cumulative incidence curve correction and survival regression calibration, and illustrate how to generate plausible parameter values through simulation. We provide an illustrative QBA example in a cohort of real-world patients with newly diagnosed multiple myeloma and provide practical guidance to apply QBA for outcome measurement error and interpret results.